Biodesix, Inc. (NASDAQ:BDSX) CFO Robin Harper Cowie Sells 24,664 Shares

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) CFO Robin Harper Cowie sold 24,664 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $0.92, for a total transaction of $22,690.88. Following the completion of the transaction, the chief financial officer now owns 246,460 shares of the company's stock, valued at $226,743.20. This trade represents a 9.10 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Biodesix Trading Up 2.3 %

BDSX stock traded up $0.02 during trading on Friday, hitting $0.99. The company had a trading volume of 199,585 shares, compared to its average volume of 496,630. The company has a quick ratio of 3.40, a current ratio of 3.40 and a debt-to-equity ratio of 1.30. The firm has a 50-day moving average price of $1.23 and a 200-day moving average price of $1.48. Biodesix, Inc. has a 12 month low of $0.86 and a 12 month high of $2.04. The stock has a market cap of $143.28 million, a price-to-earnings ratio of -2.53 and a beta of 1.06.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new stake in Biodesix during the 4th quarter worth $119,000. Northern Trust Corp grew its holdings in Biodesix by 286.5% during the 4th quarter. Northern Trust Corp now owns 169,132 shares of the company's stock worth $259,000 after acquiring an additional 125,368 shares during the period. Birchview Capital LP grew its holdings in Biodesix by 0.7% during the 4th quarter. Birchview Capital LP now owns 5,581,176 shares of the company's stock worth $8,539,000 after acquiring an additional 40,000 shares during the period. Boothbay Fund Management LLC acquired a new stake in Biodesix during the 4th quarter worth $52,000. Finally, Silverarc Capital Management LLC grew its holdings in Biodesix by 21.7% during the 4th quarter. Silverarc Capital Management LLC now owns 4,332,281 shares of the company's stock worth $6,628,000 after acquiring an additional 771,187 shares during the period. Institutional investors own 20.96% of the company's stock.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.